CVRx targets clinical integration of Barostim with hands on symposium at AAHFN2026

CVRx targets clinical integration of Barostim with hands on symposium at AAHFN2026
CVRx set for AAHFN2026 event

CVRx has announced its participation in AAHFN2026, where the company will host an interactive dinner symposium focused on the role of Advanced Practice Providers in patient selection and the adoption of Barostim therapy.

Attendees are expected to gain real world insights through case discussions and expert engagement, aiming to support the integration of Barostim into routine clinical practice.

CVRx recently celebrated its 25th Barostim implant at UNC Medical Center Chapel Hill, marking a milestone in its cardiac device therapy program (CVRx Barostim UNC milestone). The company also detailed the methodology for its BENEFIT-HF trial in a newly published peer-reviewed paper (BENEFIT-HF trial published). These initiatives reflect CVRx's ongoing focus on expanding clinical adoption and evidence for Barostim.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.